Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 20,733,000	$ 23,099,000
Prepaid expenses and other current assets	411,000	529,000
Due from related party		64,000
Minority interest investment in former subsidiary		978,000
Total current assets	21,144,000	24,670,000
Long-term assets
Property and equipment, net	22,000	12,000
Operating lease right-of-use assets	398,000
Finance lease right-of-use assets	24,000
Intangible assets, net	16,525,000	18,469,000
Other long-term assets	59,000
Total assets	38,172,000	43,151,000
Current liabilities
Accounts payable	1,995,000	934,000
Accrued compensation	283,000	274,000
Accrued clinical trial site costs	1,999,000	320,000
Operating lease liabilities	305,000
Other current liabilities	382,000	349,000
Total current liabilities	4,964,000	1,877,000
Long-term liabilities
Contingent liability for Essentialis purchase price	5,938,000	5,649,000
Other long-term liabilities	147,000
Total liabilities	23,225,000	12,738,000
Commitments and contingencies (Note 8)
Stockholders’ equity
Common stock	45,000	32,000
Additional paid-in-capital	172,708,000	157,413,000
Accumulated deficit	(157,806,000)	(127,032,000)
Total stockholders’ equity	14,947,000	30,413,000
Total liabilities and stockholders’ equity	38,172,000	43,151,000
Series B Convertible Preferred Stock [Member]
Stockholders’ equity
Preferred stock
Series A Warrant Liability [Member]
Long-term liabilities
Warrant liability		49,000
2017 PIPE Warrant Liability [Member]
Long-term liabilities
Warrant liability	10,822,000	4,563,000
2018 PIPE Warrant Liability [Member]
Long-term liabilities
Warrant liability	$ 1,354,000	$ 600,000